申请人:INSTITUT NATIONAL DE LA SANTE ET
DE LA RECHERCHE MEDICALE (INSERM)
公开号:EP2047858A1
公开(公告)日:2009-04-15
The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO:1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO:3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
本发明涉及的产品含有(i) 至少一种编码人体细胞生长抑素 2 受体蛋白 (sst2) 的核酸序列,其序列为 SEQ ID NO:1,其同源物或衍生物;(ii) 至少一种编码人脱氧胞苷激酶蛋白 (dck) 的核酸序列,其序列为 SEQ ID NO:2的同源物或其衍生物,(iii) 至少一种编码人尿苷单磷酸激酶蛋白(umk)的核酸序列,其序列为SEQ ID NO:3 的同源物或其衍生物,以及(iv) 吉西他滨,作为一种联合制剂,用于同时、单独或依次治疗受试者的癌症。